The following are some key points that we have chosen to highlight in connection with the report:

• Sales relatively in line with our expectations
• New product launches expected to accelerate growth
• Gross margin affected by import duties in the U.S.
• Strong cost control and financial position

In conclusion, Analyst Group views Genetic Analysis Q3-25 report as stable and largely in line with expectations, with 3% sales growth despite currency headwinds and quarterly fluctuations. The Company continues to strengthen its market position through new product launches and steady expansion of the GA-map® platform, including the recently introduced GA-map® MHI GutHealth test and the milestone achieved in the IBD Precision Dx project, both of which add long-term growth potential through high-margin, recurring reagent kit revenues. While import tariffs temporarily pressured gross margins, underlying profitability remains supported by strong cost control and a lean operating model. With continued product diversification, expanding diagnostic relevance, and a solid cash position of NOK 17.7m, Genetic Analysis is well positioned to drive margin expansion and sustained growth as sales ramp up in the coming quarters.

Read Analyst Group’s comment on the report here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
 
This is a press release from Analyst Group regarding the publication of a comment on Genetic Analysis. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.